Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Neumora TherapeuticsNMRA -4.58%11 Market Cap is $235.81 Mil as of Sep. 09, 2026. GuruFocus rates NMRA with a GF Score™ of 11/100. The stock has 3 warning signs investors should review. Among 1,420 Biotechnology companies, Neumora Therapeutics ranks better than 59.44% on this metric.
Neumora Therapeutics's quarterly market cap
increased
from Dec. 2025 ($311.93 Mil) to Mar. 2026 ($355.21 Mil) but then
declined
from Mar. 2026 ($355.21 Mil) to Jun. 2026 ($317.65 Mil).
Neumora Therapeutics's annual market cap
declined
from Dec. 2023 ($2,708.09 Mil) to Dec. 2024 ($1,714.13 Mil) and
declined
from Dec. 2024 ($1,714.13 Mil) to Dec. 2025 ($311.93 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Neumora Therapeutics's Enterprise Value for Today is $171.29 Mil.
Neumora Therapeutics (NAS:NMRA) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Neumora Therapeutics Market Cap Related Terms
Neumora Therapeutics Market Cap Historical Data
* Premium members only.
The historical data trend for Neumora Therapeutics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Neumora Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neumora Therapeutics Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Neumora Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where Neumora Therapeutics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Neumora Therapeutics's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neumora Therapeutics (NMRA) has a Market Cap of $235.81 Mil as of Sep. 09, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Neumora Therapeutics and its competitors. According to the industry distribution chart, Neumora Therapeutics ranks #576 out of 1420 companies in the Biotechnology industry, placing it in the top 40.6%.
Is Neumora Therapeutics' Market Cap too high?
Neumora Therapeutics' current Market Cap is $235.81 Mil. The Biotechnology industry median Market Cap is 121.38. Neumora Therapeutics' value of $235.81 Mil is 94.3% above this industry median. Based on the distribution chart, Neumora Therapeutics ranks #576 out of 1420 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Neumora Therapeutics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Neumora Therapeutics' Market Cap compare to ELDN and NAGE?
According to the Biotechnology industry distribution chart, Neumora Therapeutics ranks #576 out of 1420 companies for Market Cap. This puts Neumora Therapeutics in the upper half of its industry. The industry median Market Cap is 121.38. Neumora Therapeutics' value of $235.81 Mil is 94.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 121.38, based on 1,420 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Neumora Therapeutics's current Market Cap of $235.81 Mil is 94.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Neumora Therapeutics and its competitors. For the Biotechnology industry, the median Market Cap is 121.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neumora Therapeutics's current Market Cap is $235.81 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neumora Therapeutics stock overvalued right now?
Neumora Therapeutics (NMRA) has a current Market Cap of $235.81 Mil. The current Market Cap is $235.81 Mil and 94.3% above the Biotechnology industry median of 121.38. Neumora Therapeutics' overall GF Score™ is 11/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Neumora Therapeutics (NMRA), the current Market Cap is $235.81 Mil as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
11GF Score
Get the complete analysis for NMRA
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NMRA has been successfully added to your 
